Therapeutic strategies in antiphospholipid syndrome;Estrategias terapéuticas en el síndrome antifosfolipídico

Reumatologia Clinica

Volumn 6, Issue 1, 2010, Pages 37-42

  Cervera, Ricard ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

Anticardiolipin antibodies; Antiphospholipid antibodies; Antiphospholipid syndrome; Lupus anticoagulant

Indexed keywords

ANCROD; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; CYCLOPHOSPHAMIDE; DEFIBROTIDE; FIBRINOLYTIC AGENT; GLUCOCORTICOID; HEPARIN; IMMUNOGLOBULIN; LUPUS ANTICOAGULANT; METHYLPREDNISOLONE; PHOSPHOLIPID ANTIBODY; PROSTACYCLIN;

ANTIPHOSPHOLIPID SYNDROME; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 73149115033     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: 10.1016/j.reuma.2008.11.020     Document Type: Review

References (49)

1. In: Asherson R.A., Cervera J.C., and Shoenfeld Y. (Eds). The antiphospholipid syndrome II-autoimmune thrombosis (2002), Elsevier, Amsterdam
2. Bucciarelli S., Espinosa G., Cervera R., Erkan D., Gómez-Puerta J.A., Ramos-Casals M., et al. Mortality in the catastrophic antiphospholipid syndrome. Causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 54 (2006) 2568-2576
3. Alarcón-Segovia D., Boffa M.C., Branch W., Cervera R., Gharavi A., Khamashta M., et al. Prophylaxis of the antiphospholipid syndrome: A consensus report. Lupus 12 (2003) 499-503
4. Ginsburg K.S., Liang M.H., Newcomer L., Goldhaber S.Z., Schur P.H., Hennekens C.H., et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 117 (1992) 997-1002
5. Erkan D., Harrison M.J., Levy R., Petersson M., Petri M., Sammaritano L., et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 56 (2007) 2382-2391
6. Wahl D.G. Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholpid antibodies. Arch Intern Med 160 (2000) 2042-2048
7. Erkan D., Merrill J.T., Yazici Y., Sammaritano L., Buyon J.P., and Lockshin M.D. High thrombosis rate after fetal loss in antiphospholipid syndrome: Effective prophylaxis with aspirin. Arthritis Rheum 44 (2001) 1466-1467
8. Ruiz-Irastorza G., Egurbide M.V., Pijoan J.I., Garmendia M., Villar I., Martínez-Berriotxoa A., et al. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15 (2006) 577-583
9. a ed. Barcelona: MRA; 2006.
10. Rosove M.H., and Brewer P.M.C. Antiphospholipid thrombosis: Clinical course after the first thrombotic event in 70 patients. Ann Intern Med 117 (1992) 303-308
11. Khamashta M.A., Cuadrado M.J., Mujic F., Taub N., Hunt B.J., and Hughes G.R.V. The management of thrombosis in the antiphospholipid antibody syndrome. N Engl J Med 332 (1995) 993-997
12. Derksen R.H., De Groot P.G., Kater L., and Nieuwenhuis H.K. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 52 (1993) 689-692
13. Rance A., Emmerich J., and Fiessinger J.N. Anticardiolipin antibodies and recurrent thromboembolism. Thromb Haemost 77 (1997) 221-222
14. Schulman S., Svenungsson E., Granqvist S., and Duration of Anticoagulation Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 104 (1998) 332-338
15. Crowther M.A., Ginsberg J.S., Julian J., Denburg J., Hirsh J., Douketis J., et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome. N Engl J Med 349 (2003) 1133-1138
16. Castellino G., Cuadrado M.J., Godfrey T., Khamashta M.A., and Hughes G.R.V. Characteristics of patients with antiphospholipid syndrome with major bleeding after oral anticoagulant treatment. Ann Rheum Dis 60 (2001) 527-530
17. Brunner H.I., Chan W.S., Ginsberg J.S., and Feldman B.M. Longterm anticoagulation is preferable for patients with antiphospholipid syndrome. Result of a decision analysis. J Rheumatol 29 (2002) 490-501
18. Meroni P.L., Moia M., Derksen R.H., Tincani A., McIntyre J.A., Arnout J.M., et al. Venous thromboembolism in the antiphospholipid syndrome: Management guidelines for secondary prophylaxis. Lupus 12 (2003) 504-507
19. Ruiz-Irastorza G., Hunt B.J., and Khamashta M.A. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 57 (2007) 1487-1495
20. Albers G.W., and Tijssen J.G. Antiplatelet therapy: New foundations for optimal treatment decisions. Neurology 53 (1999) 25-31
21. Levine S.R., Salowich-Palm L., Sawaya K.L., Perry M., Spencer H.J., Winkler H.J., et al. IgG anticardiolipin antibody titers > 40 GPL and the risk of subsequent thrombo-occlusive events and death. A prospective cohort study. Stroke 28 (1997) 1660-1665
22. Verro P., Levine S.R., and Tietjen G.E. Cerebrovascular ischemic events with high positive anticardiolipin antibodies. Stroke 29 (1998) 2245-2253
23. Jacobs B.S., and Levine S.R. Antiphospholipid antibody syndrome. Curr Treat Options Neurol 2 (2000) 449-458
24. Levine J.S., Branch D.W., and Rauch J. The antiphospholipid syndrome. N Engl J Med 346 (2002) 752-763
25. The Haemostasis and Thrombosis Task Force. BCSH guidelines on oral anticoagulation. Br J Haematol 101 (1998) 374-387
26. Cervera R, Khamashta MA, Shoenfeld Y, Camps MT, Jacobsen S, Kiss E, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: A multicenter prospective study of 1,000 patients. Ann Rheum Dis. 2008 Sep 18. [Epub ahead of print].
27. Asherson R.A., Espinosa G., Cervera R., Font J., and Reverter J.C. Catastrophic antiphospholipid syndrome: Proposed guidelines for diagnosis and treatment. J Clin Rheumatol 8 (2002) 157-165
28. Asherson R.A., and Cervera R. The catastrophic antiphospholipid antibody syndrome: A review of pathogenesis, clinical features and treatment. IMAJ 2 (2000) 268-273
29. Asherson R.A., Cervera R., Piette J.C., Shoenfeld Y., Espinosa G., Petri M.A., et al. Catastrophic antiphospholipid syndrome: Clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 80 (2001) 355-376
30. Neuwelt C.M., Daikh M., Linfoot D.I., Pfister J.A., Young D.A., Robyn G., et al. Catastrophic antiphospholipid syndrome: Response to repeated plasmapheresis over three years. Arthritis Rheum 40 (1997) 1534-1539
31. Asherson R.A., Cervera R., Piette J.C., Font J., Lie J.T., Burcoglu A., et al. Catastrophic antibody syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 77 (1998) 195-207
32. Kitchens C.S. Thrombotic storm: When thrombosis begets thrombosis. Am J Med 104 (1998) 381-384
33. Kane D., McSweeney F., Swan N., and Bresnihan B. Catastrophic antiphospholipid antibody syndrome in primary systemic sclerosis. J Rheumatol 25 (1998) 810-812
34. Dosekun A.K., Pollak V.E., Glas-Greenwalt P., Kant K.S., Penovich P., Lebron-Berges A., et al. Ancrod in systemic lupus erythematosus with thrombosis. Clinical and fibrinolysis effects. Arch Intern Med 144 (1984) 37-42
35. Asherson R.A., Cervera R., De Groot P.G., Erkan D., Boffa M.C., Piette J.C., et al. Catastrophic antiphosphospholipid syndrome: International consensus statement on classification criteria and treatment guidelines. Lupus 12 (2003) 530-534
36. Shehata H.A., Nelson-Piercy C., and Khamashta M.A. Management of pregnancy in antiphospholipid syndrome. Rheum Dis Clin North Am 27 (2001) 643-659
37. Kutteh W.H. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 174 (1996) 1584-1589
38. Rai R., Cohen H., Dave M., and Regan L. Randomized controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies. BMJ 314 (1997) 253-257
39. Farquharson R.G., Quenby S., and Greaves M. Antiphospholipid syndrome in pregnancy: A randomized controlled trial of treatment. Obstet Gynecol 100 (2002) 408-413
40. Silver R.K., MacGregor S.N., Sholl J.S., Hobart J.M., Neerhof M.G., and Ragin A. Comparative trial of prednisone plus aspirin versus aspirin alone in the treatment of anticardiolipin antibody-positive obstetric patients. Am J Obstet Gynecol 169 (1993) 1411-1417
41. Pattison N.S., Chamley L.W., Birdsall M., Zanderigo A.M., Liddell H.S., and McDougall J. Does aspirin have a role in improving pregnancy outcome for women with the antiphospholipid syndrome? A randomized controlled trial. Am J Obstet Gynecol 183 (2000) 1008-1012
42. Tincani A., Branch W., Levy R.A., Piette J.C., Carp H., Rai R.S., et al. Treatment of pregnant patients with antiphospholipid syndrome. Lupus 12 (2003) 524-529
43. Balasch J., Carmona F., López-Soto A., Font J., Creus M., Fábregues F., et al. Low-dose aspirin for prevention of pregnancy losses in women with primary antiphospholipid syndrome. Hum Reprod 8 (1993) 2234-2239
44. Carmona F., Font J., Azulay M., Creus M., Fàbregues F., Cervera R., et al. Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: A multivariate analysis. Am J Reprod Immunol 46 (2001) 274-279
45. Branch D.W., Peaceman A.M., Druzin M., Silver R.K., El-Sayed Y., Silver R.M., et al. A multicenter, placebo-controlled pilot study of intravenous immunoglobulin treatment of antiphospholipid syndrome during pregnancy. Am J Obstet Gynecol 182 (2000) 122-127
46. Sanson B.J., Lensing A.W., Prins M.H., Ginsberg J.S., Barkagan Z.S., Lavenne-Pardonge E., et al. Safety of low-molecular weight heparin in pregnancy: A systematic review. Thromb Haemost 81 (1999) 668-672
47. Font J., Jiménez S., Cervera R., García-Carrasco M., Ramos-Casals M., Campdelacreu J., et al. Splenectomy for refractory Evans′ syndrome associated with antiphospholipid antibodies: Report of two cases. Ann Rheum Dis 59 (2000) 920-923
48. García-Carrasco M., Jiménez-Hernández M., Escárcega R.O., Mendoza-Pinto C., Galarza-Maldonado C., Sandoval-Cruz M., et al. Use of rituximab in patients with systemic lupus erythematosus: An update. Autoimmun Rev 8 (2008) 343-348
49. Lockshin M., Tenedios F., Petri M., McCarty G., Forastiero R., Krilis S., et al. Cardiac disease in the antiphospholipid syndrome: Recommendations for treatment. Committee consensus report. Lupus 12 (2003) 518-523